Conflict of Interest
ALS
S. Paganoni reports research grants from the National Institutes of Health, Alector Therapeutics, Biohaven, Cytokinetics, Anelixis Pharmaceuticals, Revalesio Corporation, UCB, Clene, Prilenia, Seelos Therapeutics, Calico, and Denali Therapeutics unrelated to this manuscript; consulting fees from Amylyx Pharmaceuticals, Frequency Therapeutics, SOLA Pharmaceuticals, Stealth BioTherapeutics, Orion, Roche, Janssen, and Arrowhead; honoraria from Medscape; and board membership in the Association of Academic Physiatrists. M. Quintana and M. Vestrucci are employees of Berry Consultants, LLC, report consulting fees from Amylyx Pharmaceuticals for some of the analyses described in the submitted work, and serve as consultants to numerous additional pharmaceutical and device companies. A.V. Sherman reports grants from the National Institutes of Health, US Food and Drug Administration, the ALS Association, and ALS Finding a Cure